PAPD5/7 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization

Henrik Mueller, Anaïs Lopez, Philipp Tropberger, Steffen Wildum, Josephine Schmaler, Lykke Pedersen, Xingchun Han, Yongguang Wang, Søren Ottosen, Song Yang, John A.T. Young, Hassan Javanbakht – 26 October 2018 – RG7834 is a potent, orally bioavailable small‐molecule inhibitor of hepatitis B virus (HBV) gene expression that belongs to the dihydroquinolizinone (DHQ) chemical class and uniquely blocks production of both viral DNA and antigens.

Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection

Shi Liu, Bin Zhou, Juan D. Valdes, Jian Sun, Haitao Guo – 25 October 2018 – Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured by currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), the bona fide transcription template for HBV RNAs, in infected hepatocytes.

Development of Clinical Criteria for Functional Assessment to Predict Primary Nonfunction of High‐Risk Livers Using Normothermic Machine Perfusion

Hynek Mergental, Barnaby T. F. Stephenson, Richard W. Laing, Amanda J. Kirkham, Desley A. H. Neil, Lorraine L. Wallace, Yuri L. Boteon, Jeannette Widmer, Ricky H. Bhogal, M. Thamara P. R. Perera, Amanda Smith, Gary M. Reynolds, Christina Yap, Stefan G. Hübscher, Darius F. Mirza, Simon C. Afford – 25 October 2018 – Increased use of high‐risk allografts is critical to meet the demand for liver transplantation. We aimed to identify criteria predicting viability of organs, currently declined for clinical transplantation, using functional assessment during normothermic machine perfusion (NMP).

Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection

Shi Liu, Bin Zhou, Juan D. Valdes, Jian Sun, Haitao Guo – 25 October 2018 – Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured by currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), the bona fide transcription template for HBV RNAs, in infected hepatocytes.

Primary Stent Placement for Hepatic Artery Stenosis After Liver Transplantation: Improving Primary Patency and Reintervention Rates

Ammar Sarwar, Christine Chen, Khalid Khwaja, Raza Malik, Kristin E. Raven, Jeffrey L. Weinstein, Amy Evenson, Salomao Faintuch, Robert Fisher, Michael P. Curry, Muneeb Ahmed – 25 October 2018 – Recent studies have reported high rates of reintervention after primary stenting for hepatic artery stenosis (HAS) due to the loss of primary patency. The aims of this study were to evaluate the outcomes of primary stenting after HAS in a large cohort with longterm follow‐up.

Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease

Nadim Mahmud, Abraham Shaked, Kim M. Olthoff, David S. Goldberg – 25 October 2018 – The 5‐year incidence of posttransplant hepatocellular carcinoma (HCC) recurrence is 8%‐20%. Several studies have evaluated pretransplant risk factors for HCC recurrence, but nearly all data have treated HCC as a homogeneous condition across all etiologies of liver disease despite differences in tumor biology and baseline incidence of HCC.

Subscribe to